Document Type
Article
Publication Date
3-14-2017
Description
AS-1, the TIR/BB loop mimetic, plays a protective role in cardiac ischemia/reperfusion (I/R) but the molecular mechanism remains unclear. The muscle specific caveolin3 (Cav-3) and the caveolae have been found to be critical for cardioprotection. This study aimed to evaluate our hypothesis that caveolae and Cav-3 are essential for AS-1-induced cardioprotection against myocardial I/R injury. To address these issues, we analyzed the involvement of Cav-3 in AS-1 mediated cardioprotection both in vivo and in vitro. We demonstrate that AS-1 administration significantly decreased infarct size, improved cardiac function after myocardial I/R and modulated membrane caveolae and Cav-3 expression in the myocardium. For in vitro studies, AS-1 treatment prevented Cav-3 re-distribution induced by H/R injury. In contrast, disruption of caveolae by MCD treatment or Cav-3 knockdown abolished the protection against H/R-induced myocytes injury by AS-1. Our findings reveal that AS-1 attenuates myocardial I/R injury through caveolae and Cav-3 dependent mechanism.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Citation Information
Hu, Yuanping; Zhang, Meiling; Shen, Xin; Dai, Guoliang; Ren, Danyang; Que, Linli; Ha, Tuanzhu; Li, Chuanfu; Xu, Yong; Ju, Wenzheng; and Li, Yuehua. 2017. TIR/BB-Loop Mimetic AS-1 Attenuates Cardiac Ischemia/Reperfusion Injury via a Caveolae and Caveolin-3-Dependent Mechanism. Scientific Reports. Vol.7 https://doi.org/10.1038/srep44638 PMID: 28291255
Copyright Statement
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/